Abstract
BackgroundRecent landmark trials such as DAPA-HF and EMPEROR-Reduced have led to the approval and implementation of Sodium/glucose cotransporter 2 (SGLT2) inhibitors as a first line therapy for heart failure with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
